Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disorder caused by deficiency of the enzyme iduronate-2-sulfatase (IDS). The human IDS gene is located in chromosome Xq28. This is the first report of genotype and phenotype characterization of 49 Hunter patients from 40 families of Argentina. Thirty different alleles have been identified, and 57% were novel. The frequency of de novo mutations was 10%. Overall, the percentage of private mutations in our series was 75%.
Introduction
Mucopolysaccharidosis type II (MPS II, Hunter disease, MIM 309900) is an X-linked lysosomal storage disorder caused by deficiency of the enzyme iduronate-2-sulfatase (IDS). Clinical manifestations are coarse Molecular Genetics and Metabolism Reports 1 (2014) 401-406 [2] . An IDS pseudogene (IDSP1) has been detected 20 kb distal to the telomeric side from the functional gene, whose sequences are highly homologous to exons 2 and 3 and introns 2,3 and 7 of the IDS gene [3] . To date, over 500 different mutations associated with MPS II have been identified [Human Gene Mutation Database (HGMD); http://www.hgmd.org/].
We report the results of genotype and phenotype characterization of 49 Hunter patients of 40 families from Argentina.
Materials and methods

Patients
Forty nine Hunter patients and their mothers (only 28 of mother samples where available) from 40 families were included in this study. Parents of the patients gave their informed consent previous to the participation in the study. MPS II diagnosis was confirmed by clinical examination and deficient IDS activity (activity of arilsulfatase B was normal in all cases, ruling out multiple sulfatase deficiency). Phenotype of MPSII patients has been classified into attenuated (non-neuronopathic) or severe (neuronopathic) according to the clinical evidence of cognitive or developmental involvement.
IDS genomic DNA analysis
Genomic DNA was extracted from EDTA blood using a QIAamp DNA Blood Mini kit (Qiagen, Valencia, CA, USA). The 9 exons of the IDS gene including exon/intron boundaries were amplified by PCR using specific primers as described [3] . Sequencing was carried out in both directions in a MegaBASE 1000 sequencer (Amersham Biosciences, Sunnyvale, CA, USA).
Recombination between IDS and IDSP1 leading to any inversion mutation was analyzed by a PCR amplification assay as described [4] .
IDS cDNA analysis
Total cellular RNA was isolated from blood leukocytes by means of a total RNA isolation system (Macherey Nagel, Duren, Germany). The isolated RNA samples were reverse transcribed using a specific primer, according to the method of Jonsson [5] and then amplified in 2 overlapping fragments and sequenced.
Results and discussion
Until now, we have found the mutation in all the patients analyzed from Argentina. Thirty different MPS II alleles have been identified in a cohort of 49 Argentinean patients from 40 families: 18 missense (60%), 5 splicing (17%), 3 short deletions (10%), 2 nonsense mutations (7%), 1 complex rearrangement (a gene-pseudogene recombination leading to inversion) (3%) as well as 1 gross gene deletion (3%) ( Table 1) . We have not detected any insertions.
Of the mutations in this cohort, 17 out of 30 different alleles (57%) were novel (missense: p.Pro228Gln, p.Lys295Ile, p.Asp198Asn, p.Trp345Arg, p.Ser142Tyr, p.Gly134Glu, p.Gly312Asp, p.Thr214Met, p.Gln465Leu, p.Pro157Ser; splicing: c.508-1G N A, c.241-5A N T, c.708 + 1 g N a; nonsense: p.Glu274X; and short deletions: c.908_909delCT, c.411delT, c.22_37del16pb).
The effect of novel missense mutations was analyzed by different means. They are all predicted to be probably damaging, as analyzed by the prediction tool PolyPhen, and are localized in conserved aminoacids between human and murine IDS but found in patients with both attenuated and severe phenotypes. Glycines 134 and 312 are highly conserved among human sulfatases. Mutations found by us at these positions introduce negative charged aminoacids. Although the change in the structure of these highly conserved aminoacids is high, both patients display an attenuated phenotype. The mutations p.Pro228Gln and p.Pro157Ser in severe patients result from the replacement of a rigid nonpolar aminoacid by a polar one. The rest of the novel missense mutations are not localized in conserved aminoacids, however the effect in the phenotype is more devastating.
Previously described mutations detected by us were p.Arg468Gln, p.Ala85Thr, p.Ser333Leu, p.Pro120His, p.Ser61Pro, p.Leu339Pro, p.Asp478Gly, p.Gln465X, p.Arg443X, the splice mutations c.1122C N T, c.1181-1 g N a, and the recombination gene-pseudogene.
We found 3 novel splicing mutations. The mutation c.508-1 g N a was found in a patient with an attenuated phenotype. At the molecular level, the mutation produced a predominant alternative transcript and a minor quantity of the correct transcript. The mutant transcript results from the disruption of the 3′ original splice-site leading to the deletion of exon 5. The presence of the correct mRNA, although in minor quantity, would explain the less severe clinical manifestations observed in this patient. On the other side, the splicing mutations c.241-5a N t and c.708 + 1 g N a, each generate a unique mRNA product, whose sequence corresponds to the complete deletion of exons 3 and 5, respectively, and are associated with a severe phenotype.
In one patient, two different "neighbor" mutations (p.Arg468Gln + p.Gln465Leu) were found. The mother was a carrier of both mutations, but not the grandmother and the 4 maternal aunts. Few other reports described the presence of "neighbor" mutations [6] . The finding of these two close mutations in the patient and his mother but not in the grandmother suggests that they are de novo mutations in a mutation-prone region and reinforces the idea that they arose simultaneously.
Three patients had a complete gene deletion. None of the flanking markers tested were detected, suggesting that the deletion spans more than 20 kb upstream and 7 kb downstream of the IDS locus, and includes the IDSP1 locus. No atypical symptoms of Hunter syndrome were found in these patients, indicating that the deletion did not compromise contiguous genes. The phenotype of these patients is the severe form of the disease. The same phenotype was observed for the three of the patients who exhibited a recombination between gene and pseudogene.
The absence of the probands' mutations in their mother suggests that in the three cases, the mutations occurred de novo (10%). However, the possibility of germinal mosaicism could not be ruled out. The theoretical rate calculated by the Bayesian methods for this condition would be 33%, so the value found in our cohort is much less. In the cohort reviewed by Froissart et al., they found values of de novo mutations close to the expected in any X chromosomal disease in which male reproductive fitness is extremely low [2] . The low value found in our group could be because much of the patients from Argentina were diagnosed because of a previous family history of MPS II, meaning there are still many undiagnosed patients in Argentina. We also found a low rate of the polymorphism in exon 4 c.438C N T, only in 4 families (10%) as compared to the frequency reported in normal controls of around 30% [3] .
The percentage of private mutations in our series was 75%, a high proportion as usually seen in other series.
Although genotype-phenotype correlation is difficult to establish, it is worth mentioning that both missense (p.Ser61Pro, p.Ala85Thr, p.Gly134Glu, p.Gly312Asp, p.Asp478Gly) and splice mutations (c.1122C N T, c.508-1G N A) were associated with non-neuronopathic ("attenuated") phenotype. From our series of 30 alleles, 7 (23%) were found associated with mild forms. Three of the mutations associated with the non-neurological phenotype, are new (c.508-1 g N a, p.Gly134Glu, p.Gly312Asp).
This is the first report of mutations of Hunter patients from Argentina. Our results provide further evidence of mutational heterogeneity of the IDS gene observed in patients with MPS II.
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